That’s why I say you live in your own HGEN world. 50% of their 390 population is 195 patients, if you followed other stocks at all, you would have known this. Also, you make statements like they will not meet primary end point as a matter of fact. The fact that their trial was not changed at all based on interim review says that you are absolutely wrong. If it could not meet primary endpoint, the DSMC would have stopped the trial already, that’s their job. Your statement has no real basis. This is an investment board so people can share ideas for good investments, if you’re not going to listen at all, why bother?
Market Data 
Markets 
AI
